Navigation Links
Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
Date:2/17/2011

Delta-like ligand-4 (Dll4), a novel angiogenesis target, is in a Phase 1 study in patients with advanced malignancies.

REGN668, an antibody to the interleukin-4 receptor (IL-4R), a target for allergic and immune conditions, has completed Phase 1 testing in healthy volunteers.  A Phase 1b study in patients with atopic dermatitis is underway and a Phase 2 study in asthma is planned.

REGN910, an antibody to angiopoietin-2 (ANG2), a novel angiogenesis target, is in a Phase 1 study in oncology.  

REGN475, an antibody to nerve growth factor (NGF), has completed a Phase 2 trial in osteoarthritis of the knee. In December 2010, the Company was informed by the FDA that a case confirmed as avascular necrosis of a joint was seen in another company's anti-NGF program.
The FDA believes this case, which follows previously-reported cases of joint replacements in patients on an anti-NGF drug candidate being developed by another pharmaceutical company, provides evidence to suggest a class-effect and has placed REGN475 on clinical hold.  There are currently no ongoing trials with REGN475 that are either enrolling or treating patients.  

REGN728 and REGN846, whose targets remain undisclosed, have entered clinical development.

Financial ResultsThe Company's total revenues increased to $133.7 million in the fourth quarter of 2010 from $96.8 million in the same quarter of 2009 and to $459.1 million for the full year 2010 from $379.3 million for the full year 2009.  The increases were primarily due to higher collaboration revenue in 2010 in connection with the Company's antibody collaboration with sanofi-aventis.  In addition, the increase in the fourth quarter of 2010 was partly due to the recognition of $20.0 million in substantive milestone payments from Bayer HealthCare.

Net product sales of ARCALYST® in the fourth quarter of 2010 were $5.3 million, compared to $5.0 m
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and SAN DIEGO , Dec. ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... measurement solutions for cardiovascular applications, today announced that they have ... Philips will commence a tender offer to acquire all of ... per share, or a total equity purchase price of USD ...
(Date:12/17/2014)... NASHVILLE, Tenn. , Dec. 17, 2014  Strategic ... health management software solutions, today announced a strategic agreement ... the New Jersey regional marketplace.  ... and enhance the health and wellness solutions QualCare brings ... and the surrounding region. QualCare ...
(Date:12/17/2014)... SCOTTSDALE, Ariz. , Dec. 17, 2014 /PRNewswire/ ... of state-of-the-art interactive music products, today announced that ... Ltd, a leading manufacturer and supplier of innovative ... As part of the agreement, RSL ... Facility bundled solution specifically configured for use within ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3
... LITTLE FALLS, N.J., Nov. 5 CANTEL MEDICAL CORP. ... Krakauer, President & CEO, will be presenting at the Sidoti ... formal presentation is scheduled for 9:05 AM ET on Friday, ... a Q & A session immediately following the presentation. In ...
... Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today announced ... voreloxin orphan drug designation for the treatment of acute ... 2 clinical trials of voreloxin in AML: a single-agent ... elderly AML patients unlikely to benefit from standard induction ...
Cached Medicine Technology:Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 2Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 3
(Date:12/21/2014)... Over the past 39 years, NES Health has ... departments across the nation, from quality of medical care ... an innovative suite of tools, systems, and programs that ... patient experience. , NES Health, a leading national ... for hospitals, announced the development and launch of its ...
(Date:12/21/2014)... 21, 2014 CannabisClassifieds.com celebrates marijuana’s new legal ... only one of its kind, the site has provided its ... for 14 years running. It uniquely combines the benefits ... cannabis readily available to the masses. Assuring the potent ... golden ring of public approval. , Shane Chattin, ...
(Date:12/20/2014)... BambooIndustry.com is a leading ... has announced its bamboo flooring promotion for the ... from certified suppliers, and offers the best bamboo ... the current promotion, all customers can enjoy a ... say they know BambooIndustry.com from press releases. , ...
(Date:12/20/2014)... Dress company LunaDress has recently announced its ... Christmas Sale, offering big discounts on all of its special ... idea to own a perfect wedding gown. If you have ... then come to LunaDress. Many different wedding dress styles and ... website now and enjoy the current special offer, up to ...
(Date:12/20/2014)... VogueQueen.com, a leading wedding dress wholesaler and retailer, has ... 2015. Great discounts are now offered on all of ... a discount, up to 80% off, when they place ... 2015. , VogueQueen.com has recently released its new arrival ... Many customers worldwide like VogueQueen’s special designs which feature ...
Breaking Medicine News(10 mins):Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:VogueQueen Big Sale Online For The Coming 2015 2
... -- Readmission rates have increased in many hospitals across ... elite academic medical centers, new research shows. About one ... within 30 days of being discharged for a medical ... for penalties -- reduced payments for readmissions -- for ...
... exposure to stressors in the Neonatal Intensive Care Unit ... and function of very preterm infants. According to the ... a journal published by Wiley-Blackwell on behalf of the ... experienced early exposure to stress displayed decreased brain size, ...
... , MONDAY, Oct. 3 (HealthDay News) -- The rate of ... rose dramatically over two decades, according to new government research. ... become the leading form of HPV-linked cancers, the researchers noted. ... percent of oral cancer samples tested positive for HPV. By ...
... Reporter , MONDAY, Oct. 3 (HealthDay News) -- Babies born very ... -- are five times more likely than full-term newborns to have ... study, based on Swedish medical databases, also found that being born ... seizure disorder as adults. Babies born as late as 35 to ...
... the strength of its synapses -- the connections between neurons ... a discovery that challenges conventional wisdom on the brain mechanisms ... brain "rhythm," or frequency, for changing synaptic strength. And further, ... to a different optimal frequency for learning. ...
... HealthDay Reporter , MONDAY, Oct. 3 (HealthDay News) ... recommended vaccination guidelines for their children, opting instead for ... delaying shots. And parents who do follow official ... schedule, according to new research. The findings alarm ...
Cached Medicine News:Health News:Hospital Readmission Rates on the Rise in Older Adults: Study 2Health News:Hospital Readmission Rates on the Rise in Older Adults: Study 3Health News:Preterm infants exposed to stressors in NICU display reduced brain size 2Health News:HPV-Linked Oral Cancers on the Rise, Study Finds 2Health News:HPV-Linked Oral Cancers on the Rise, Study Finds 3Health News:Preemies May Be at Higher Risk of Epilepsy Later in Life 2Health News:Preemies May Be at Higher Risk of Epilepsy Later in Life 3Health News:How the brain makes memories: Rhythmically! 2Health News:How the brain makes memories: Rhythmically! 3Health News:Some U.S. Parents Ignoring Vaccination Guidelines 2Health News:Some U.S. Parents Ignoring Vaccination Guidelines 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: